HIV and AIDS News

DTG: Millions yet to lay hands on new HIV drug in SA

Green light for long acting PrEP
WHO urges countries to roll out CAB-LA at faster pace(Freepik)
Written by Ndivhuwo Mukwevho

Despite studies proving that the new HIV treatment drug – dolutegravir (DTG) – is highly effective at suppressing the virus in the body with fewer side effects, millions of South Africans remain on the old efavirenz regimen.

In 2019, the National Department of Health began replacing efavirenz with the dolutegravir regimen. However, of the 7.9 million people living with HIV, only three million are on the new regimen. Of the almost eight million HIV-positive people, 5,645 120 are on antiretroviral therapy (ART).

In 2018, the World Health Organisation (WHO) recommended using DTG as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.

DTG the obvious choice

Nelson Dlamini, Communications Manager at the South African National Aids Council (SANAC), stated that DTG is more effective and cheaper. 

“Both medicines are effective for the treatment of HIV. However, the DTG-based regimen is more tolerable and a cheaper regimen to procure. The National Department of Health published the new ART guidelines in October 2019, which inform clinicians of the changes to the management of HIV,” stated Dlamini.

Dlamini said the efavirenz regime is not well tolerated by patients owing to its side effects profile.

“When patients experience side effects, they sometimes stop taking their medicines to get some relief. The Dolutegravir regimen is well tolerated. It has minimal side effects and has a high genetic barrier to resistance,” explained Dlamini.

He further stated: “When patients discontinue their HIV treatment, we refer to this as nonadherence, which has the risk of accelerating the development of drug resistance. When patients develop HIV drug resistance to first-line treatment, their medication must be changed to second-line or third-line treatments, which are less tolerated and usually more expensive.”

Potential to improve lives

According to UNAIDS, 28,2 million people were accessing antiretroviral therapy as of 30 June 2021. It further stated that 37.7 million people globally were living with HIV in 2020.

Dlamini said that the dolutegravir-based regimen has the potential to improve lives based on its several benefits. They include the provision of rapid viral suppression, the high genetic barrier to resistance, and fewer side effects. It’s also a smaller tablet that is easier to swallow.

“The DTG regimen contains 50mg compared to efavirenz which is 600mg. The quantity of DTG Active Pharmaceutical Ingredients (API), 50mg, is lower, which reduces costs,” said Dlamini.

The SA lowdown

Health Ministry spokesperson Foster Mohale said over 3 198 757 South Africans moved to dolutegravir by the end of March.

“All 52 district facilities are moving to the DTG-based regimen in line with the National ART guideline. Public health facilities have TLD (tenofovir disoproxil, lamivudine and dolutegravir) stock in their pharmacies,” he said.

Mohale said, “The country rolled out DTG-based regimen based on two phases. The unplanned analysis in the Tsepano study in Botswana influenced the decision. It suggested that the prevalence of neural-tube defects were slightly higher with DTG exposure than with other types of ART at conception.” – Health-e News

 

About the author

Ndivhuwo Mukwevho

Ndivhuwo Mukwevho is citizen journalist who is based in the Vhembe District of Limpopo province. He joined OurHealth in 2015 and his interests lie in investigative journalism and reporting the untold stories of disadvantaged rural communities. Ndivhuwo holds a Bachelor of Arts degree in Media Studies from the University of Venda and he is currently a registered student with UNISA.

Leave a Comment